BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
This meets the minimum requirement for their exchange offer. Now, BioNTech will provide ADSs or cash for any fractional ADSs to the shareholders who participated, and they've also opened up another offering period until December 18.
Once that period wraps up, they'll go ahead with a post-offer reorganization.
BNTX is currently trading at $97.01, up $0.90 or 0.94 percent on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.